Summary of Key Issues
Plant Doctor has been preparing for its IPO for 9 years, and now the status has moved to “inquiry stage.” However, there are six underlying issues that have been overlooked by public opinion: a vague brand positioning (is it a cosmetics brand or a retail service provider?), the risk of inventory accumulation due to a no-franchise-fees model, a shrinking target customer base, a conflict between product ingredients and consumer perceptions, unclear ownership of member assets, and long-term concerns regarding strong-person governance. These issues have a more significant impact on its long-term value than the surface-level problems such as revenue stagnation and compliance issues, making this 9-year IPO journey highly uncertain.
Detailed Analysis
1. Ambiguous Brand Positioning: Cosmetics or Beauty Salon?
Everyone assumes Plant Doctor is a cosmetics brand, comparing it to companies like Perlaia and Betaine. However, it actually resembles a hybrid of Fanwenhua and Watsons: offline stores account for 70% of its revenue, and the distribution model accounts for 64.7%. The stores also offer skin testing and care services, with sales staff focusing on both service and product promotion.
- Dramatic Difference in Valuation Based on Positioning: Cosmetics brands generate profits through brand premiums, with gross margins exceeding 70% and P/E ratios of 20-30 times; retail service providers rely on store operations, with maximum gross margins of 40% and P/E ratios of only 8-12 times.
- Plant Doctor Straddles the Two: With a comprehensive gross margin of 60% (with direct-operated stores having margins over 70%), the brand emphasizes itself as a “high-altitude plant skincare brand” to maximize its valuation. However, if the market sees through its retail nature, its valuation could be significantly reduced.
2. The No-Franchise-Fees Trap: Not About Rapid Expansion, but Unmanageable Inventory
The no-franchise-fee model sounds attractive, but the brand’s profits come from the difference in supply prices, leading to a mismatch between the brand’s intentions and those of its franchisees. The brand wants franchises to purchase more goods (to increase revenue), while franchises want to sell more products (to make profits).
- Inventory Accumulation as the Norm: Some media reports indicate that Plant Doctor requires initial inventory purchases of at least 80,000 units, with a monthly mandatory reserve of 100,000 units. Goods shipped to franchise stores are counted as revenue, but if they don’t get sold to consumers, they become inventory.
- The Truth Behind Revenue Stagnation: Revenue has been stable at 2.1 billion yuan for three years, not due to lack of growth, but possibly because channel inventories are already full—franchisees are reluctant to purchase more.
3. Growth Limitations: Not Due to Weak Online Presence, but a Shrinking Customer Base
The market attributes Plant Doctor’s slow growth to its weak online presence, but the real issue is a shrinking customer base. Its core customers are women aged 35-55 from third- and fourth-tier cities, while younger people in these areas are moving to first- and second-tier cities, leaving the older population behind.
- Data Supports This Trend: The seventh national census shows that 70% of the 376 million migrant population is aged 15-45, with a decreasing number of eligible women in these regions.
- Reasons for Store Closures: Plant Doctor claims to be “actively optimizing inefficient stores,” but this may be because good locations have been exhausted, leaving it without new customers. Relying solely on offline expansion is no longer viable; the brand needs to find ways to capture the consumer benefits of experiential services in lower-tier markets.
4. The Paradox of Ingredient Claims: High-Altitude Plants Cannot Support Anti-Aging Promises
Plant Doctor promotes “high-altitude plant anti-aging,” but consumers’ perceptions are hard to change. They generally associate “plant skincare” with mild hydration and believe that anti-aging requires more advanced ingredients like retinol and alpha-hydroxy acids.
- Example Comparison: Milk advertisements show cows grazing in fields, but in reality, cows in captivity produce higher-quality milk. Consumers associate “outdoor cows” with better milk, and brands dare not challenge this perception.
- Plant Doctor’s Dilemma: No amount of advertising can convince consumers that plants can effectively fight aging; the brand’s messaging is unclear compared to competitors like Perlaia (focusing on early anti-aging) and Betaine (for sensitive skin).
5. The Risks of Strong-Person Governance: Can the Company Survive Without the Founder?
Founder Xie Yong controls 89.71% of the voting rights, making all major decisions. This is a typical example of strong-person governance:
- Organizational Weakness: The executive team is not well-known, and research and development personnel have decreased from 166 to 125, with reduced R&D investment—this indicates a decline in organizational vitality.
- Succession Concerns: Xie Yong has led the company for 32 years, and the prospectus does not mention any plans for his successors. The franchise chain is heavily reliant on central control; without a systematic management structure after his retirement, the entire system could face issues.
- Long-Term Risk: Compliance issues can be addressed, and performance stagnation can be managed, but the generational gap in organizational capabilities is a critical factor in a company’s success or failure—more fatal than any short-term problem.
In Conclusion
Plant Doctor’s IPO journey seems to focus on compliance and revenue issues, but the real challenges lie in underlying logical contradictions: unclear positioning, flawed models, shrinking customer bases, cognitive conflicts, and governance risks. If these problems are not resolved, even a successful IPO will not guarantee sustainable long-term growth. Investors should ask not just whether the company can go public, but where its next growth trajectory lies—after all, the numbers in the prospectus represent the past; the future is what truly matters.